Thermo Fisher Scientific to Acquire Solventum’s Purification and Filtration Business for $4.1 Billion

On February 25, Waltham, Massachusetts, the global service science leaderThermo Fisher Scientific(NYSE: TMO) Announced that it has reached a definitive agreement with Solventum (NYSE:SOLV)Thermo Fisher Scientific Inc. has reached an agreement to acquire Solventum's purification and filtration business for approximately $41 billion in cash. Solventum expects the transaction to be neutral to earnings per share in 2025, with net proceeds estimated at around $34 billion, primarily to be used for debt repayment.

Solventum's Purification and Filtration Business is a leading supplier of purification and filtration technologies used in biopharmaceutical production as well as medical technology and industrial applications. The Solventum business operates globally with branches in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, employing approximately 2,500 colleagues. In 2024, Solventum’s purification and filtration business generated about $1 billion in revenue.

Solventum's purification and filtration business is highly complementary to Thermo Fisher Scientific's bioproduction business. Today, Thermo Fisher Scientific boasts a leading portfolio in cell culture media and single-use technologies. Solventum’s innovative filtration product portfolio expands Thermo Fisher Scientific's capabilities in biologics development and manufacturing, covering both upstream and downstream workflows.

Marc N. Casper, Chairman, President, and Chief Executive Officer of Thermo Fisher Scientific, stated:"The increase in Solventum's business aligns highly with our company’s strategy and will create significant value for our customers and shareholders. Solventum's portfolio of solutions will be valued by customers and further demonstrate our disciplined capital deployment strategy, which has a strong track record in creating shareholder value."

Casper continued to state:"As a trusted partner to our customers, Solventum’s purification and filtration business will expand and add differentiated capabilities to our bioprocessing portfolio, allowing us to better serve customers in this fast-growing market. We look forward to welcoming our new colleagues to Thermo Fisher Scientific."

Solventum CEO Bryan Hanson said:"Selling the purification and filtration business is part of the third phase of our transformation plan, following an in-depth analysis of the value and strategic alignment of the business. This transaction will reinforce our strategic priorities and key metrics while reducing leverage and significantly strengthening our balance sheet. It also enables us to invest in the innovation, initiatives, and talent needed to execute our mission and create value for shareholders."

Mr. Hanson continued to say:"Solventum is committed to ensuring a smooth transition for employees, customers, and other stakeholders. We believe Thermo Fisher Scientific will provide the purification and filtration business, which offers filters and membranes used in biopharmaceuticals and medical technology, microelectronics, food and beverage products, as well as drinking water manufacturing, representing the strategic investment and resources needed to sustain growth and deliver customer solutions."

The transaction is expected to be completed by the end of 2025, subject to customary closing conditions and regulatory approvals. Upon completion of the transaction, Solventum's purification and filtration business will become part of Thermo Fisher Scientific's Life Sciences Solutions segment.

The purification and filtration business of Solventum, as part of Thermo Fisher Scientific, is expected to generate mid-to-high single-digit organic growth. The application of the PPI business system will drive strong profit expansion and meaningful synergies. This reflects very powerful first-day cost synergies when Solventum's distribution overhead is replaced by Thermo Fisher’s lower internal operating costs, partially offset in the first year by one-time stand-up costs. Thermo Fisher Scientific expects to achieve approximately $125 million in adjusted operating income through revenue and cost synergies by the fifth year after closing the transaction. The anticipated long-term business growth, profit expansion opportunities, and synergy realization make the financial returns of the transaction highly compelling, with a double-digit internal rate of return.

Follow the official account below to see the world!